



ELSEVIER

Contents lists available at ScienceDirect

Annals of Hepatology

journal homepage: www.elsevier.es/annalsofhepatology

Letter to the editor

COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern on cases with underlying liver problem


We would like to share ideas on the report "COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis [1]." Aguilar et al. concluded that "We will definitively continue to be updated and "tuned-up" while further research in critical areas like etiopathogenesis and emerging therapies for VITT unfolds in this new fascinating but poorly understood arena of clinical thrombosis.....[1]." The adverse effect of COVID-19 vaccine is the present focus at present. The thrombohemostatic disturbance might occur. As noted in the editorial, there are many possible pathomechanisms [1]. We would like to add another possible underlying cause of thrombohemostatic disorder, the vaccine-induced hyperviscosity [2]. The rapid increase of immunity after vaccination might occur, and high blood viscosity can alter the normal thromohemostasis process [3]. The problem might arise in anyone receiving the vaccination. For the patient with underlying liver disease, a more risk might be expected.

Of several underlying pathophysiology, many patients with underlying liver disease usually have a high blood bilirubin level. Since hyperbilirubinemia is associated with increased blood viscosity, a patient with underlying liver disease and jaundice, such as cholangiocarcinoma or chronic active hepatitis, might have an increased chance of post COVID-19 vaccination hyperviscosity and thrombohemostatic

disorder. Closed monitoring of the possible adverse effect of COVID-19 among a person with underlying jaundice should be required.

Conflict of interest

None

References

- [1] Aguilar MP, Langner AL, Panduro A, Uribe M. COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis. *Ann Hepatol* 2021;23C:100356.
- [2] Joob B, Wiwanitkit V. Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19. *Clin Appl Thromb Hemost* 2021 Jan-Dec;27:10760296211020833.
- [3] Nwose EU, Richards RS, Bwititi P, Butkowski E. Serum bilirubin and lipoprotein-a: how are these associated with whole blood viscosity? *Redox Rep* 2012;17(1):8-13.

Pathum Sookaromdee*

Viroj Wiwanitkit

Private Academic Consultant, Bangkok Thailand

Honorary professor, Dr DY Patil University, Pune, India

*Correspondence: Pathum Sookaromdee, Private Academic Consultant, Bangkok Thailand
E-mail address: pathumsook@gmail.com (P. Sookaromdee).